News

Even with government programs like Social Security, many people seek to save their own money for retirement, often setting the goal of reaching the $1 million mark by the time they reach retirement

Even with government programs like Social Security, many people seek to save their own money for retirement, often setting the goal of reaching the $1 million mark by the time they reach retirement

Even with government programs like Social Security, many people seek to save their own money for retirement, often setting the goal of reaching the $1 million mark by the time they reach retirement

On July 18, Pfizer (NYSE: PFE) announced that it is forging a strategic alliance with Flagship Pioneering, a venture capital (VC) firm, in which the pair would invest $50 million each into 10

On July 18, Pfizer (NYSE: PFE) announced that it is forging a strategic alliance with Flagship Pioneering, a venture capital (VC) firm, in which the pair would invest $50 million each into 10

Equity markets can be volatile, erratic, and not always entirely rational. That sometimes results in shares of companies not being adequately priced. And when these stocks trade for less than

Equity markets can be volatile, erratic, and not always entirely rational. That sometimes results in shares of companies not being adequately priced. And when these stocks trade for less than

Since the beginning of 2023, equity markets have been experiencing what could be the start of a bull run. Buying shares of growth stocks is an excellent move for investors looking to ride this wave

When you think about biotech leaders, the name Biogen (NASDAQ: BIIB) may come to mind. Over the years, this biotechnology giant built a powerful multiple sclerosis (MS) treatment platform that has

When you think about biotech leaders, the name Biogen (NASDAQ: BIIB) may come to mind. Over the years, this biotechnology giant built a powerful multiple sclerosis (MS) treatment platform that has

When you think about biotech leaders, the name Biogen (NASDAQ: BIIB) may come to mind. Over the years, this biotechnology giant built a powerful multiple sclerosis (MS) treatment platform that has

If you're shopping for a healthcare stock that promises growth, the medical technology space could offer some good choices. Many suffered at certain points during the earlier days of the pandemic as

Shares of the brain-health specialist Sage Therapeutics (NASDAQ: SAGE) are having a tough trading session today. Specifically, the biotech's stock was down by approximately 13% on heavy volume as of

Shares of the brain-health specialist Sage Therapeutics (NASDAQ: SAGE) are having a tough trading session today. Specifically, the biotech's stock was down by approximately 13% on heavy volume as of

Shares of the brain-health specialist Sage Therapeutics (NASDAQ: SAGE) are having a tough trading session today. Specifically, the biotech's stock was down by approximately 13% on heavy volume as of

Companies that possess the characteristic of consistency are arguably the foundation upon which all income portfolios should be built. That is because businesses that reliably grow over time can

Companies that possess the characteristic of consistency are arguably the foundation upon which all income portfolios should be built. That is because businesses that reliably grow over time can

There's one main downside to the tremendous performance of the stock market so far in 2023. Many stocks are now priced for perfection. And unfortunately, perfection is rarely attainable.

The good

Typically, when a publicly traded company reports an estimates-beating quarter, its stock price rises in reaction. There are always exceptions, though, and on Tuesday it was Biogen's (NASDAQ: BIIB)

Typically, when a publicly traded company reports an estimates-beating quarter, its stock price rises in reaction. There are always exceptions, though, and on Tuesday it was Biogen's (NASDAQ: BIIB)

Typically, when a publicly traded company reports an estimates-beating quarter, its stock price rises in reaction. There are always exceptions, though, and on Tuesday it was Biogen's (NASDAQ: BIIB)

Image source: The Motley Fool.

Biogen (NASDAQ: BIIB)Q2 2023 Earnings CallJul 25, 2023, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com

Image source: The Motley Fool.

Biogen (NASDAQ: BIIB)Q2 2023 Earnings CallJul 25, 2023, 8:00 a.m. ET

Operator

Continue reading

Source Fool.com